profit from every €100 of sales.
€0€100
Sartorius Stedim Biotech
€222.80-1.76% today
+7.7% since Dec 22, 25
1-year low €151.501-year high €228.40
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay €81.63 for every €1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Sartorius Stedim Biotech sold, what it kept, and what it did with the cash.
Sales went from €3.49 billion in 2022 to €2.97 billion in 2025, with €266 million of profit last year.
SalesProfit
Sartorius Stedim Biotech handed back 22% of the cash it generated last year.
€67M
Free cash flow 2025€299M
Bought back its own shares–
Paid as dividends€67M
Cash vs. debt€426M vs. €2.6B
Sartorius Stedim Biotech vs. similar companies
Sartorius Stedim Biotech grows the slowest of these 5 and is the most expensive for its profits.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| Sartorius Stedim Biotech | 81.6× · Very expensive | ||
 Intuitive Surgical | 53.4× · Expensive | ||
 EssilorLuxottica Société anonyme | 35.6× · Expensive | ||
 Becton, Dickinson and | 35.0× · Expensive | ||
 Medline | 45.4× · Expensive |
AI analysis
An AI analyst reads Sartorius Stedim Biotech's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 3,493 | 2,776 | 2,780 | 2,968 | |
| 1,817 | 1,234 | 1,207 | 1,345 | |
| 1,055 | 471 | 398 | 539 | |
| 1,331 | 756 | 671 | 831 | |
| 876 | 310 | 175 | 266 | |
| 9.51 | 3.37 | 1.81 | 2.73 | |
| 52.0% | 44.5% | 43.4% | 45.3% | |
| 30.2% | 17.0% | 14.3% | 18.2% | |
| 25.1% | 11.2% | 6.3% | 9.0% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 5,065 | 7,730 | 8,256 | 7,984 |
| Cash | 107 | 117 | 679 | 426 |
| Total debt | 1,136 | 3,682 | 2,870 | 2,599 |
| Total liabilities | 2,551 | 5,056 | 4,233 | 3,858 |
| 2,449 | 2,639 | 3,987 | 4,091 | |
| 92 | 92 | 97 | 97 | |
| 24.0% | 6.2% | 4.0% | 5.7% | |
| 35.8% | 11.8% | 4.4% | 6.5% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 612 | 746 | 815 | 692 | |
| 431 | 474 | 340 | 393 | |
| 182 | 273 | 475 | 299 | |
| Dividends paid | 116 | 133 | 67 | 67 |
| – | – | 2 | – | |
| – | – | – | – |
Valuation
- 81.6×
- –
- –
- 4.2×
- 7.3×
- 72.5×
- 28.7×
- 1.4%
- 1.2%
- 0.3%
Profitability
- 45.3%
- 18.2%
- 9.0%
- –
- 5.7%
- 10.0%
- –
- –
- –
- –
Growth
- −5.3%
- −34.0%
- –
- –
- +1.8%
Financial health
- 2.6×
- 0.64
- –
- 3.7×
- 1.02
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 48%of 952
Top 27%of 883
Bottom 12%of 576
Bottom 9%of 870
Top 49%of 985
0.3%of the share price, paid each year
On $1,000 invested$3a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
25.3% of its profit
Room to growStretchedMore than it earns: 22.4%
News
Utilities flash oversold signal as Treasury yields dim dividend appealSeeking Alpha · Sep 6, 2026The newest story we have is from Sep 6, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
36No pass
Benjamin Graham
30No pass
Philip Fisher
28No pass
Peter Lynch
21No pass
Joel Greenblatt
2No pass
Charlie Munger
30No pass
Terry Smith
30No pass
Questions about Sartorius Stedim Biotech
Is Sartorius Stedim Biotech a good stock to buy?
A solid business, priced as if everything goes right. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Sartorius Stedim Biotech AI analysis
What does Sartorius Stedim Biotech do?
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. It is in Medical Instruments & Supplies, based in Aubagne, France, with 10,456 employees.
Does Sartorius Stedim Biotech pay a dividend?
Yes. At today's price the dividend is 0.3% a year, about 25% of its yearly profit. In 2025 it paid out €67.1 million in dividends.
Is Sartorius Stedim Biotech stock halal?
Yes. Sartorius Stedim Biotech passes our halal screen: its business is permitted and its debt is 12% of its market value, under the 30% limit. How we check
Who are Sartorius Stedim Biotech's competitors?
The largest listed companies in the same industry are Intuitive Surgical, EssilorLuxottica Société anonyme, Becton, Dickinson and and Medline. The peers table on this page compares their profit, growth and price with Sartorius Stedim Biotech's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.